Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | STAT1 | P42224 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039813 | 0.80 | LMNA (0.38) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL5036333 | 0.80 | CYP2D6 (0.37) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL5044391 | 0.70 | PIK3CD (0.43) | MAPTCYP1A2PIK3CGNPC1RAB9A | |
| SCHEMBL5039846 | 0.70 | MAPT (0.36) | MAPT | |
| SCHEMBL5036390 | 0.69 | ELANE (0.36) | MAPTNPC1STAT1RAB9ASMN1; SMN2 | |
| SCHEMBL5036537 | 0.69 | LMNA (0.39) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL5039413 | 0.68 | MAPT (0.36) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL5039517 | 0.67 | MAPT (0.31) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL5039566 | 0.66 | PIK3CG (0.41) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL23794254 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | claimed |
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7303590-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1715840-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER, GAMBLE COMPANY, THE | 2005-09-08 | — | — | US | disclosed |
| WO-2005077324-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, KLK5, CKMT1A; CKMT1B | MAPT 439/4885LMNA 351/4885CYP1A2 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.